BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17584152)

  • 1. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
    Atanasov AG; Odermatt A
    Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):125-40. PubMed ID: 17584152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
    Saiah E
    Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
    Oppermann U
    Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
    Odermatt A; Nashev LG
    J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):1-13. PubMed ID: 20100573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.
    Chapman KE; Seckl JR
    Neurochem Res; 2008 Apr; 33(4):624-36. PubMed ID: 17963039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
    Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
    Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
    Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
    Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
    Seckl JR; Walker BR
    Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
    Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
    J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.
    Wu L; Qi H; Zhong Y; Lv S; Yu J; Liu J; Wang L; Bi J; Kong X; Di W; Zha J; Liu F; Ding G
    Endocr J; 2013; 60(9):1047-58. PubMed ID: 23759754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.